HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) today announced the completion of its acquisition of Alchemee, formerly The Proactiv Company (TPC), from Galderma. The acquisition includes Alchemee’s business and assets worldwide, including the Proactiv® brand.
“This acquisition demonstrates Taro’s commitment to strengthening our position in the over-the-counter dermatology space,” said Uday Baldota, Taro’s CEO. “In addition to adding Proactiv® to our product portfolio, we are also gaining the omni-channel marketing capabilities and expertise of the Alchemee team. We look forward to working with them to continue Proactiv®’s legacy as an iconic brand synonymous with acne care.”
Alchemee's flagship brand, Proactiv, is America’s #1 acne routine1 and has been used and trusted by millions around the world for more than 25 years.
“We are excited for Alchemee and its marquee brand, Proactiv®, to join the expansive Taro portfolio of prescription and over-the-counter dermatology products,” said Shannon Pappas, Global Head of Alchemee. “This strategic move further positions Alchemee for continued growth in the skincare space.”
- Based on 2021 FDM/Specialty retail sales.
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
Forward-Looking Statements
Some of the information contained in this press release may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Neither Taro nor Alchemee has any obligation to publicly update or revise any forward-looking statements.